Preview

Научно-практическая ревматология

Расширенный поиск

Мониторинг больных системной красной волчанкой: общая характеристика и дискуссионные вопросы (по материалам рекомендаций Канадской ассоциации ревматологов)

https://doi.org/10.14412/1995-4484-2019-255-264

Полный текст:

Аннотация

В статье подробно изложены 15 новых рекомендаций Канадской ревматологической ассоциации, посвященных клиническому мониторингу больных системной красной волчанкой (СКВ). При их разработке была впервые использована система классификации и оценки качества рекомендаций GRADE (Grading of Recommendations Assessment, Development, and Evaluation). Рекомендации по специализации врача, оценке кардиоваскулярного риска, концентрации анти-Ro/SSA и анти-La/SSB антител в период беременности и ежегодной вакцинации против вируса гриппа рассматриваются как сильные; по оценке активности болезни и индекса повреждения, ультразвуковому исследованию сонных артерий, диагностике остеопороза, остеонекроза, допплерографии маточного и фетоплацентарного кровотока во время беременности, скринингу рака шейки матки, вирусных гепатитов В и С у пациентов с СКВ – как условные.

Об авторах

Т. А. Панафидина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А.



Т. В. Попкова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А.


С. К. Соловьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А.


Список литературы

1. Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. С. 429-81 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. Moscow: GEOTAR-Media; 2010. P. 429-81 (In Russ.)].

2. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340-50. doi: 10.1056/NEJM200108023450506

3. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. doi: 10.1038/nrrheum.2016.137. Epub 2016 Aug 25.

4. Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002;61(5):409-13. doi: 10.1136/ard.61.5.409

5. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69:1269-74. doi: 10.1136/ard.2009.117200. Epub 2009 Nov 5.

6. Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 113-36 [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. P. 113-36 (In Russ.)].

7. Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018;45(10):1426-39. doi: 10.3899/jrheum.171459. Epub 2018 Sep 1.

8. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336(7652):1049-51. doi: 10.1136/bmj.39493.646875.AE

9. Fiander M, McGowan J, Grad R, et al. Interventions to increase the use of electronic health information by healthcare practitioners to improve clinical practice and patient outcomes. Cochrane Database Syst Rev. 2015:CD004749. doi: 10.1002/14651858.CD004749.pub3

10. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744. doi: 10.1136/bmj.a744

11. Schü nemann HJ, Oxman AD, Brozek J, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-10. doi: 10.1136/bmj.39500.677199.AE

12. Blaauw AA, Schuwirth LW, van der Vleuten CP, et al. Assessing clinical competence: recognition of case descriptions of rheumatic diseases by general practitioners. Br J Rheumatol. 1995;34:375-9. doi: 10.1093/rheumatology/34.4.375

13. Gamez-Nava JI, Gonzalez-Lopez L, Davis P, Suarez-Almazor ME. Referral and diagnosis of common rheumatic diseases by primary care physicians. Br J Rheumatol. 1998;37:1215-9. doi: 10.1093/rheumatology/37.11.1215

14. Narain S, Richards HB, Satoh M, et al. Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. Arch Intern Med. 2017;164:2435-41. doi: 10.1001/archinte.164.22.2435

15. Ward MM. Association between physician volume and in-hospital mortality in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:1646-54. doi: 10.1002/art.21053

16. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-40. doi: 10.1002/art.1780350606

17. Petri M, Kim MY, Kalunian KC, et al. For the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550-8. doi: 10.1056/NEJMoa051135

18. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.

19. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86:447-58.

20. Vitali C, Bencivelli W, Isenberg DA, et al. The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol. 1992;10:541-7.

21. Fellows of Harvard College. SLE Activity Measure-Revised (SLAM-R) 1998.

22. Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum. 1996;39(3):363-9. doi: 10.1002/art.1780390303

23. Keeling S, Vandermeer B, Medina J, et al. Measuring disease activity and damage with validated metrics: a systematic review on mortality and damage in systemic lupus erythematosus. J Rheumatol. 2018 Jun 21 [In press]. doi: 10.3899/jrheum.171310

24. Tselios K, Sheane BJ, Gladman DD, Urowitz MB. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: a systematic review. J Rheumatol. 2016;43:54-65. doi: 10.3899/jrheum.150460. Epub 2015 Nov 15.

25. Anderson TJ, Gregoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32:1263-82. doi: 10.1016/j.cjca.2016.07.510. Epub 2016 Jul 2

26. Панафидина ТА, Попкова ТВ, Алекберова ЗС и др. Значение факторов риска и С-реактивного белка в развитии атеросклероза у женщин с системной красной волчанкой. Клиническая медицина. 2006;84(10):49-54 [Panafidina TA, Popkova TV, Alekberova ZS, et al. The significance of risk factors and C-reactive protein in the development of atherosclerosis in women with systemic lupus erythematosus. Klinicheskaya Meditsina. 2006;84(10):49-54 (In Russ.)].

27. Попкова ТВ, Алекберова ЗС, Александрова ЕН и др. Факторы риска кардиоваскулярных нарушений и атеросклероза при системной красной волчанке. Научно-практическая ревматология. 2004;42(4):10-4 [Popkova TV, Alekberova ZS, Aleksandrova EN, et al. Cardiovascular disturbances and atherosclerosis risk Fасtore in systemic lupus erythematosus. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2004;42(4):10-4 (In Russ.)]. doi: 10.14412/1995-4484-2004-795

28. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore). 1992;71(5):291-302. doi: 10.1097/00005792-199209000-00004

29. Urowitz MB, Gladman D, Ibanez D, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16(9):731-5. doi: 10.1177/0961203307081113

30. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77-95. doi: 10.1016/j.semarthrit.2012.12.002. Epub 2013 Feb 17.

31. Kim CH, Al-Kindi SG, Jandali B, et al. Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2017;103(3):227-33. doi: 10.1136/heartjnl-2016-309561. Epub 2016 Sep 9.

32. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. doi: 10.1016/S0195-668X(03)00114-3

33. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-81. doi: 10.1093/eurheartj/ehw106

34. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-97. doi: 10.1007/s00198-007-0543-5. Epub 2008 Feb 22.

35. www.iscd.org/official-positions/2013-iscd-officialpositionspediatric

36. Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol. 2009;28:579-85. doi: 10.1007/s10067-009-1105-3. Epub 2009 Feb 18.

37. Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999;42:882-90. doi: 10.1002/1529-0131(199905)42:5<882::AIDANR6>3.0.CO;2-C

38. Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol. 2003;22:318-23. doi: 10.1007/s10067-003-0743-0 39. Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, et al. Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol. 2009;28:65-70. doi: 10.1007/s10067-008-0984-z. Epub 2008 Aug 1.

39. Pineau CA, Urowitz MB, Fortin PJ, et al. Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus. 2004;13:436-41. doi: 10.1191/0961203303lu1036oa

40. Borba VZ, Vieira JG, Kasamatsu T, et al. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int. 2009;20:427-33. doi: 10.1007/s00198-008-0676-1. Epub 2008 Jul 4.

41. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev. 2006;5:114-7. doi: 10.1016/j.autrev.2005.05.009

42. Toloza S, Cole D, Gladman D, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010;19:13-9. doi: 10.1177/0961203309345775. Epub 2009 Nov 6.

43. Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:2044-50. doi: 10.1002/art.21110

44. Шкиреева СЮ, Лесняк ОМ, Зоткин ЕГ. Бессимптомные ком- прессионные переломы позвонков у женщин в постменопаузе с системной красной волчанкой. Научно-практическая рев- матология. 2017;55(1):26-31 [Shkireeva SYu, Lesnyak OM, Zotkin EG. Asymptomatic vertebral compression fractures in postmenopausal women with Systemic lupus erythematosus. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):26-31 (In Russ.)]. doi: 10.14412/1995-4484-2017-26-31

45. Mont MA, Glueck CJ, Pacheco IH, et al. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol. 1997;24:654-62.

46. Oinuma K, Harada Y, Nawata Y, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis. 2001;60:1145-8. doi: 10.1136/ard.60.12.1145

47. Ehmke TA, Cherian JJ, Wu ES, et al. Treatment of osteonecrosis in systemic lupus erythematosus: a review. Curr Rheumatol Rep. 2014;16:8. doi: 10.1007/s11926-014-0441-8

48. Nakamura J, Harada Y, Oinuma K, et al. Spontaneous repair of asymptomatic osteonecrosis associated with corticosteroid therapy in systemic lupus erythematosus: 10-year minimum follow-up with MRI. Lupus. 2010;19:1307-14. doi: 10.1177/0961203310372951. Epub 2010 Jul 6.

49. Mont MA, Zywiel MG, Marker DR, et al. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am. 2010;92:2165-70. doi: 10.2106/JBJS.I.00575

50. Aranow C, Zelicof S, Leslie D, et al. Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol. 1997;24:2318-22. doi: 10.1016/S0883-5403(97)90075-9

51. Hungerford DS, Jones LC. Asymptomatic osteonecrosis: should it be treated? Clin Orthop Relat Res. 2004;429:124-30. doi: 10.1097/01.blo.0000150275.98701.4e

52. Hussein S, Suitner M, Beland-Bonenfant S, et al. Monitoring of osteonecrosis in systemic lupus erythematosus: a systematic review and metaanalysis. J Rheumatol. 2018 Oct;45(10):1462-76. doi: 10.3899/jrheum.170837. Epub 2018 Jul 1.

53. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685-96. doi: 10.1016/j.autrev.2014.01.053. Epub 2014 Jan 24.

54. Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163:153-63. doi: 10.7326/M14-2235

55. McDonald EG, Bissonette L, Ensworth S, et al. Monitoring of systemic lupus erythematosus pregnancies: a systematic literature review. J Rheumatol. 2018 Oct;45(10):1477-90. doi: 10.3899/jrheum.171023. Epub 2018 Jul 15.

56. Кошелева НМ, Алекберова ЗС. Неонатальная волчанка. Современная ревматология. 2015;9(4):92-7 [Kosheleva NM, Alekberova ZS. Neonatal lupus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(4):92-7 (In Russ.)]. doi: 10.14412/1996-7012-2015-4-92-97

57. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology. 2006;45:332-8. doi: 10.1093/rheumatology/kei159

58. Farine D, Granovsky-Grisaru S, Ryan G, et al. Umbilical artery blood flow velocity in pregnancies complicated by systemic lupus erythematosus. J Clin Ultrasound. 1998;26:379-82. PMID: 9783243.

59. Dickinson J, Tsakonas E, Conner Gorber S, et al; Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. CMAJ. 2013;185:35-45. doi: 10.1503/cmaj.121505. Epub 2013 Jan 7.

60. Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmun Rev. 2014;13:730. doi: 10.1016/j.autrev.2014.03.001. Epub 2014 Mar 20.

61. Dugue P, Lynge E, Rebolj M. Increased risk of high-grade squamous intraepithelial lesions in systemic lupus erythematosus: additional data from Denmark. Autoimmun Rev. 2014;13:1241-2. doi: 10.1016/j.autrev.2014.08.004. Epub 2014 Aug 20.

62. Aikawa N, Trudes G, Campos L, et al. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients. Lupus. 2013;22:1394-8. doi: 10.1177/0961203313505926. Epub 2013 Sep 27.

63. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and metaanalysis by etiology. J Infect Dis. 2012;206:1250-9. doi: 10.1093/infdis/jis48765. www.phac-aspc.gc.ca/naci-ccni/flu-2015-grippe-eng.php

64. Conti F, Rezai S, Valesini G. Vaccination and rheumatic disease. Autoimmun Rev. 2008;8(2):124-8. doi: 10.1016/j.autrev.2008.07.007

65. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998;41(10):1828-34. doi: 10.1002/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-T

66. Klippel JH, Karsh J, Stahl NI, et al. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum. 1979;22(12):1321-5. doi: 10.1002/art.1780221201

67. Ивашкин ВТ, Ющук НД, Маевская МВ, и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(3):58-88 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(3):58-88 (In Russ.)].

68. Garf El A, Zorkany El B, Gheith R, et al. Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward. Rheumatol Int. 2012;32:2691-5. doi: 10.1007/s00296-011-2014-8. Epub 2011 Jul 27.

69. Mohan P, Rajasekaran M, Ramanathan P, Venkataraman J. Prevalence of hepatitis C virus antibodies in systemic lupus erythematosus. Eur J Gastroenterol Hepatol. 2009;21:1437-8.

70. Abu-Shakra M, El-Sana S, Margalith M, et al. Hepatitis B and C viruses serology in patients with SLE. Lupus. 1997;6:543-4. doi: 10.1177/096120339700600612

71. Ahmed MM, Berney SM, Wolf RE, et al. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci. 2006;331:252-6. PMID: 16702794.

72. Mitwalli AH, Hayat A, Alwakeel J, Hammad D. Effects of concomitant hepatitis C virus infection in patients with underlying lupus nephritis on long-term renal outcome. Nephrol Dial Transplant. 2012;27:627-32. doi: 10.1093/ndt/gfr327. Epub 2011 Jul 18.

73. Perlemuter G, Cacoub P, Sbai A, et al. Hepatitis C virus infection in systemic lupus erythematosus: a case-control study. J Rheumatol. 2003;30:1473-8.

74. Ивашкин ВТ, Ющук НД, Маевская МВ и др. Рекомендации по диагностике и лечению взрослых больных гепатитом С. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013;23(2):41-71 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, et al. Hepatitis C diagnostics and treatment guidelines in adults. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;23(2):41-71 (In Russ.)].


Для цитирования:


Панафидина Т.А., Попкова Т.В., Соловьев С.К. Мониторинг больных системной красной волчанкой: общая характеристика и дискуссионные вопросы (по материалам рекомендаций Канадской ассоциации ревматологов). Научно-практическая ревматология. 2019;57(3):255-264. https://doi.org/10.14412/1995-4484-2019-255-264

For citation:


Panafidina T.A., Popkova T.V., Solovyev S.K. Monitoring patients with systemic lupus erythematosus: general characteristics and discussion questions (according to the Canadian Rheumatology Association recommendations). Rheumatology Science and Practice. 2019;57(3):255-264. (In Russ.) https://doi.org/10.14412/1995-4484-2019-255-264

Просмотров: 46


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)